{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T06:13:03Z","timestamp":1767939183640,"version":"3.49.0"},"reference-count":22,"publisher":"S. Karger AG","issue":"1","license":[{"start":{"date-parts":[[2016,11,4]],"date-time":"2016-11-04T00:00:00Z","timestamp":1478217600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"},{"start":{"date-parts":[[2016,11,4]],"date-time":"2016-11-04T00:00:00Z","timestamp":1478217600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Haematol"],"published-print":{"date-parts":[[2017]]},"abstract":"<jats:p>Single-agent bortezomib (B) has shown activity in heavily pretreated patients with relapsed\/refractory indolent lymphoma. On the basis of these findings, we performed a phase II study of B combined with rituximab (R) in patients with relapsed follicular lymphoma (FL). Forty-five patients with fairly good prognostic profiles were enrolled from 2007 to 2011 and received a total of 6 cycles of the B+R combination. The endpoints were the overall response rate (ORR), progression-free survival (PFS), duration of remission (DoR), overall survival (OS), and toxicity evaluation. When considering all the enrolled patients the ORR was 64%. At 5 years, the estimated PFS, DoR, and OS were 34, 49, and 70%, respectively. After excluding the 7 R-na\u00efve patients, the ORR was 58%, with a PFS of 19 months. The most common grade &gt;2 toxicities were thrombocytopenia (18%), peripheral neuropathy (13%), and neutropenia (2%). Our study shows the feasibility, long-term efficacy, and excellent tolerability of the B+R combination. We are aware that our study has specific limitations, such as the small sample size consisting of patients with a relatively good prognostic profile. However, because FL patients will be treated with subsequent chemotherapy regimens, a well-tolerated and effective chemotherapy-free therapy could be considered an additional tool for long-term disease control.<\/jats:p>","DOI":"10.1159\/000449052","type":"journal-article","created":{"date-parts":[[2016,11,7]],"date-time":"2016-11-07T22:01:30Z","timestamp":1478556090000},"page":"7-14","source":"Crossref","is-referenced-by-count":4,"title":["A Multicenter Phase II Study of Twice-Weekly Bortezomib plus Rituximab in Patients with Relapsed Follicular Lymphoma: Long-Term Follow-Up"],"prefix":"10.1159","volume":"137","author":[{"given":"Alessia","family":"Bari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raffaella","family":"Marcheselli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Marcheselli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabel","family":"Alvarez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samantha","family":"Pozzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Ferri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Lazzaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Fragasso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santo","family":"Neri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Baldini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelo Michele","family":"Carella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Angrilli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Guariglia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriele","family":"Buda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caterina","family":"Stelitano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Sacchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on behalf of the Gruppo Italiano Studio Linfomi (GISL)","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2016,11,4]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2005.11.003"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22740"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.111.089920"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2015.1.82"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.3696"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22649"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2006.03.005"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-010-1283-3"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2006.09.004"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.01.133"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/cas.12735"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.050"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.6789"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-08-233155"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07775.x"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.11.015"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70150-4"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-5-67"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12915"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(89)90015-9"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-12-4434"}],"container-title":["Acta Haematologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/449052","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/karger.com\/aha\/article-pdf\/137\/1\/7\/3895582\/000449052.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/karger.com\/aha\/article-pdf\/137\/1\/7\/3895582\/000449052.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T17:09:08Z","timestamp":1745428148000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000449052"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,4]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,1,10]]},"published-print":{"date-parts":[[2017,1,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000449052","archive":["Portico"],"relation":{},"ISSN":["0001-5792","1421-9662"],"issn-type":[{"value":"0001-5792","type":"print"},{"value":"1421-9662","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,4]]}}}